Live Webcast Scheduled to Begin at 9 am EDT Today
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.
Aldeyra will present new preclinical data from investigational RASP modulators in animal models for obesity, atopic dermatitis, inflammatory pain, and alcoholic hepatitis. In the diet-induced model of obesity, ADX-629 decreased weight and fat mass alone and in combination with a GLP-1 agonist. In the oxazolone model of atopic dermatitis, RASP modulators ADX-629, ADX-246, and ADX-248 demonstrated activity in reducing skin thickness and erosion, and in reducing spleen to body weight ratio. In the carrageenan model of inflammatory pain, ADX-246 increased tolerance to mechanical and thermal pain, and decreased joint swelling. Consistent with previously released data from ADX-629 in a model of alcoholic hepatitis, ADX-246 reduced levels of fibrosis and fat in liver.
"The new data released today support the expansion of our novel RASP platform into clinical indications that may include fat-mass-targeted weight loss and inflammatory pain, highlighting the breadth of potential product candidate opportunities afforded by modulating RASP levels," stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra.
Based on recent discussions with the U.S. Food and Drug Administration (the FDA), Aldeyra intends to initiate a potentially pivotal Phase 2/3 clinical trial of investigational product candidate ADX-2191 (methotrexate injection, USP) in patients with retinitis pigmentosa due to rhodopsin misfolding mutations. The potential activity of ADX-2191 in retinitis pigmentosa is supported by results from a Phase 2 clinical trial, announced in 2023, which demonstrated improvements from baseline in retinal sensitivity following treatment. An overview of the unmet medical need in retinitis pigmentosa will be provided by Ramiro Maldonado, M.D., Principal Investigator of the Phase 2 clinical trial and Assistant Professor of Ophthalmology, Vitreoretinal Diseases, and Surgery at Duke University.
"Due to loss of vision and dramatic impact on quality of life, retinitis pigmentosa remains a highly significant unmet medical need in retinal disease," stated Dr. Maldonado. "Even with the advent of gene therapy, cell therapy, and other new approaches not yet approved by the FDA for treatment, a safe and effective drug that could slow the progression of retinitis pigmentosa is in critical demand."
Research & Development Day Webcast Information
Aldeyra's Research & Development Day will take place from 9:00 am to 1:00 pm EDT today, Thursday, April 25, 2024, in New York City. A live audio webcast and slide presentation will be accessible from the "Investors & Media" section of the Aldeyra website at for 90 days following the event.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the potential treatment of immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Aldeyra's future expectations, plans, and prospects, including without limitation statements regarding: the goals, opportunity, and potential for reproxalap, ADX-2191, and other product candidates; the outcome and expected timing and the results of Aldeyra's planned clinical trials, including planned and ongoing clinical trials for reproxalap and ADX-2191; the outcome and timing of the FDA's review, acceptance and/or approval of a NDA resubmission for reproxalap and the adequacy of the data included in the original NDA; and the potential NDA resubmission. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "on track," "scheduled," "target," "design," "estimate," "predict," "contemplates," "likely," "potential," "continue," "ongoing," "aim," "plan," or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. All of Aldeyra's development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and other factors that could delay the initiation, enrollment, or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra's clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; delay in or failure to obtain regulatory approval of Aldeyra's product candidates, including as a result of the FDA not accepting Aldeyra's regulatory filings, issuing a complete response letter, or requiring additional clinical trials or data prior to review or approval of such filings or in connection with resubmissions of such filings; the ability to maintain regulatory approval of Aldeyra's product candidates, and the labeling for any approved products; the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Aldeyra's product candidates in clinical trials focused on the same or different indications; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; uncertainty as to Aldeyra's ability to commercialize (alone or with others) and obtain reimbursement for Aldeyra's product candidates following regulatory approval, if any; the size and growth of the potential markets and pricing for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and future revenue, the timing of future revenue, the sufficiency or use of Aldeyra's cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra's product candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's commercialization, marketing and manufacturing capabilities and strategy; Aldeyra's ability to establish and maintain development partnerships; Aldeyra's ability to successfully integrate acquisitions into its business; Aldeyra's expectations regarding federal, state, and foreign regulatory requirements; political, economic, legal, social, and health risks, public health measures, and war or other military actions, that may affect Aldeyra's business or the global economy; regulatory developments in the United States and foreign countries; Aldeyra's ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra's business and the market in which it operates; and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Aldeyra's Annual Report on Form 10-K for the year ended December 31, 2023, which is on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at https://www.sec.gov/. Additional factors may be described in those sections of Aldeyra's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, expected to be filed with the SEC in the second quarter of 2024, and Aldeyra's other filings with the SEC.
In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Contacts Investor & Media:
David Burke
Tel: (917) 618-2651
investorrelations@aldeyra.com
今日、EDt午前9時からライブウェブキャストが予定されています
マサチューセッツ州レキシントン--(BUSINESS WIRE)--Aldeyra Therapeutics Inc.(ナスダック:ALDX)(アルデイラ)は、ニューヨーク市で投資家や金融アナリストを迎え、RASP調節プラットフォームおよび遺伝性網膜色素変性症の治療に向けたパイプラインの最近の開発に関する報告を行うAldeyra 2024 Research & Development Dayを開催する予定です。
アルデイラは、肥満、アトピック性皮膚炎、炎症性疼痛、アルコール性肝炎の動物モデルで調査中のRASP modulatorの新しいプレクリニックデータを発表する予定です。 肥満誘発モデルでは、ADX-629がGLP-1アゴニストと単独および併用で体重および脂肪質量を減少させました。アトピック性皮膚炎のオキサロンモデルでは、RASP modulators ADX-629、ADX-246、ADX-248は、皮膚厚さや浸食、脾臓重量比の減少に活性が示されました。炎症性疼痛のカラギーナンモデルでは、ADX-246が機械的および熱痛に対する耐性を増大させ、関節腫れを減少させました。以前に発表されたアルコール性肝炎モデルにおけるADX-629の結果と一致して、ADX-246は、肝臓中の線維化および脂肪のレベルを低下させました。
"今日発表された新しいデータは、RASPレベルを変調することにより、脂肪量の減少や炎症性疼痛を含む臨床適応を拡大することを支持し、RASPレベルを変調することによる多様な製品候補の可能性を強調しています。"と、AldeyraのTodd C. Brady万.D., Ph.D.、CEOが述べました。
米国食品医薬品局(FDA)との最近の協議に基づき、Aldeyraは、ロドプシン蛋白質の誤り折り畳み突然変異による網膜色素変性症の患者を対象とした、試験薬剤候補ADX-2191(メトトレキサート注射、USP)の潜在的に決定的な第2相/第3相臨床試験を開始することを意図しています。網膜色素変性症に対するADX-2191の潜在的な活性は、治療後の網膜感受性の改善を示した第2相臨床試験の結果によって支持されています。網膜色素変性症の未解決の医療ニーズについては、ラミロ・マルドナード、D.D., アシスタントプロフェッサー(Ophthalmology,Vitreoretinal Diseases, and Surgery)、デューク大学のPhase 2臨床試験および主要研究者によって概説されます。
"視力の喪失と生活の質に大きな影響を与える網膜色素変性症は、依然として網膜疾患における重要な未解決の医療ニーズです"と、マルドナード博士は述べています。"FDAに承認されていない遺伝子治療、細胞治療、その他の新しい方法が導入されたとしても、網膜色素変性症の進行を遅らせることができる安全で有効な薬剤は、重要な要求されています。"
リサーチ&デベロップメント・デー
Aldeyra's Research & Development Dayは、2024年4月25日(木)午前9:00から午後1:00までEDtニューヨーク市で開催されます。ライブオーディオウェブキャストおよびスライドプレゼンテーションは、イベント後90日間、Aldeyraのウェブサイトの"投資家&メディア"セクションからアクセスできます。
Aldeyraについて
Aldeyra Therapeuticsは、免疫関連および代謝性疾患の治療に向けた革新的療法を発見することに専心するバイオテクノロジー企業です。今後の製品は、単一のターゲットを直接抑制または活性化することではなく、タンパク質システムを変調するものであり、同時に複数の経路を最適化し、毒性を最小限に抑えることを目指しています。製品候補には、免疫関連および代謝性疾患の潜在的な治療のためのRASP(reactive aldehyde species) modulators ADX-629、ADX-246、ADX-248、および化学的に類似した分子が含まれます。既存の製品候補には、ドライアイ症候群とアレルギー性結膜炎の潜在的な治療のためのRASP modulatorであるreproxalap、および網膜色素変性症の潜在的な治療のための新しい配合物であるADX-2191が含まれます。
免責事項声明
本リリースには、Aldeyraの将来の期待、計画、展望に関する声明を含みます。これらの前向きな声明には、Aldeyraの製品の目標、機会、および潜在的な製品候補に関する声明、製品候補の治療に対するAldeyraの計画されたおよび進行中の臨床試験、Aldeyraの製品候補のFDAによる承認、および承認後のアルデイラの製品候補の販売および製造に関する規制要件、販売および市場受け入れ、および競合の期待、Aldeyraの成長戦略、会社の商業化、マーケティング、および製造の能力と戦略、Aldeyraの開発提携を確立および維持する能力、Aldeyraの財務状況、銀行資源、および追加の資金ニーズに関する予測、Aldeyraの知的財産権の保護、またはFDAに承認された製品および対象の商品ラベルに関する現在および将来の規制要件、アルデイラの事業・市場・美更の予想トレンドと課題、およびその他のリスクと不確実性要因が含まれます。
SECに記載されている上記のリスクとAldeyraのその他の記載に加え、その他の未知の要因や予測できない要因がAldeyraの結果に影響する可能性があります。将来に関する声明は保証できず、実際の結果はそのような声明と異なる場合があります。このリリースの情報は、このリリースの日付のみ提供され、Aldeyraは法律に従って新しい情報、将来のイベント、またはその他の理由により、このリリースに含まれる将来に関する声明を更新することはありません。
IR問合せ先: 投資家&メディア:
David Burke
電話:(917) 618-2651
investorrelations@aldeyra.com